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Peritoneal dialysis during peritonitis. Peritonitis during perito-
neal dialysis is the most frequent complication associated with
this dialysis technique. We studied patients undergoing perito-
neal dialysis when they were without peritonitis and during epi-
sodes of clinical infection. Peritonitis was associated with a sig-
nificantly decreased dialysate effluent volume, increased absorp-
tion of glucose, clearance of urea and creatinine, and protein loss
in the dialysate effluent. We suggest that the changes occurring
to the peritoneal dialyzing surface with peritonitis might be ex-
plained by alterations in peritoneal blood flow, effective mem-
brane surface area, or permeability.
Dialyse péritonéale au cours des péritonites. La péritonite au
cours de Ia dialyse péritonéale est Ia complication Ia plus fré-
quente de cette technique. Nous avons étudié des malades
soumis a la dialyse péritonéale alors qu'ils étaient indemnes de
péritonite et au cours d'épisodes d'infection clinique. La périto-
nite a été associée a une diminution significative du volume de
dialysat effluent, une augmentation de l'absorption de glucose,
de la clearance de l'urée et de la créatinine, et de la fuite de
protéines dans l'eflluent. Nous suggérons que les modifications
qui affectent Ia surface péritonéale dialysante au cours de la pé-
ritonite puissent &re expliquées par des modifications du debit
sanguin péritonéal, de la surface membranaire efficace ou de Ia
perméabilité.
Intermittent peritoneal dialysis has become in-
creasingly important in the management of patients
with end-stage renal disease, both as a primary mo-
dality of therapy and as a backup technique for con-
tinuous ambulatory peritoneal dialysis. Although
there have been several advances in dialysis tech-
nology, peritonitis continues to be a major adverse
complication of intermittent peritoneal dialysis af-
fecting patient health [1]. It has been postulated that
the major nutritional consequences of peritonitis
are due to the increased protein loss in dialysate ef-
fluent secondary to peritoneal inflammation, a de-
creased appetite as a consequence of illness in con-
junction with an already fragile nutritional status,
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and a general catabolic state secondary to infection.
Although several authors have suggested that in-
creased protein losses occur, there is little data to
support this contention [2-5]. We investigated the
effect of peritonitis occurring during peritoneal dial-
ysis upon protein losses in the dialysate effluent, sol-
ute clearances, glucose absorption, and dialysate ef-
fluent volume.
Methods
Nine patients (five females, four males; mean
age, 44.4 5.4 years; age range, 22 to 70 years)
undergoing intermittent peritoneal dialysis or con-
tinuous ambulatory peritoneal dialysis via a chronic
indwelling catheter were studied in the Clinical Re-
search Center of the University of Mississippi. Pa-
tients underwent study exchanges when clinically
well and during episodes of peritonitis.
Peritonitis was diagnosed when signs of abdomi-
nal tenderness were present accompanied by either
an elevated dialysate cell count or a peritoneal cul-
ture yielding organisms, or both of these [6].
Dialysis technique. All dialysate solutions con-
tained 1.5% glucose concentration (Dianeal®, Tray-
enol Laboratories, Deerfield, Illinois) and 250 U of
heparin per liter of dialysate. Potassium chloride
was added as required.
(1) Control exchanges. Two liters of dialysate,
warmed to body temperature, were infused by grav-
ity over 10 mm, remained within the intraperitoneal
cavity 30 mm, then were drained over 20 mm. Sam-
ples of dialysate were collected from the mixed
drainage after measurement in a graduated cylinder.
Blood was sampled at the start and finish of study
exchanges. All antihypertensive medications were
withdrawn the day of study.
(2) Peritonitis exchanges. Prior to study ex-
changes, these patients underwent a series of ap-
proximately ten 1-liter exchanges (consisting of in-
fusion to dialysate followed by drainage) until
symptoms were relieved and the dialysate was no
Peritoneal dialysis during peritonitis 461
longer turbid. These washout exchanges contained
heparin and potassium chloride with an antibiotic.
Patients were returned to the dialysis schedule out-
lined after the 1-liter exchanges; the antibiotic was
continued.
Following the rapid exchanges of dialysate, sam-
ples were collected from the dialysate effluent of the
60-mm exchanges. Blood was sampled at the start
of the rapid exchanges, and all oral medications
were withheld. Table 1 lists antibiotics instilled i.p.
for episodes of peritonitis. The following doses
were used: tobramycin sulfate, 10 mg per 2 liters of
dialysate; cephalothin sodium, 250 mg per 2 liters;
vancomycin, 75 mg per 2 liters, ampicillin, 200 mg
per 2 liters.
Chemical analyses. Concentrations of urea,
creatinine, and glucose in serum and dialysate, and
serum proteins were determined by autoanalyzer
techniques. Dialysate protein concentration was de-
termined by trichloroacetic precipitation [7]. Dialy-
sate sodium concentration was measured by flame
photometer.
To measure glucose absorption and sodium loss
or gain with dialysis, it was necessary to determine
the dialysate concentrations and infusion volume.
Because dialysate is infused with glucose mono-
hydrate, we determined the true glucose concentra-
tion by presampling 45 bags of dialysate, and we
found it to be 1294 12 mg/dl. Similarly, we found
the infused sodium to be 134 0.4 mEq/liter.
The volume of infused dialysate was 2066 ml, de-
termined by subtracting the weight of a full bag
(2148 2, N = 48) from the weight of an empty bag
(65 0.2, N = 60) and factoring for the ratio of the
weight of deionized water to dialysate (0.99).
Calculations and statistics. Peritoneal solute
clearances were calculated as drainage volume (ml)
x drainage concentrationlserum concentration X
time (mm). Blood samples were obtained at the
start and finish of control exchanges and were inter-
polated to the start of the exchange. The initial val-
ue was used to calculate peritoneal clearances dur-
ing peritonitis exchanges. This has the effect of
lowering the calculated clearance, because the
serum concentration used was the highest value.
The true value actually decreases with dialysis. Pro-
tein loss per exchange was calculated by multi-
plying the concentration in the dialysate by the
drainage volume. Glucose absorption from dialy-
sate and sodium removal with dialysis were calcu-
lated by subtracting the infused amount from the
amount in the dialysate drainage.
The patients underwent repetitive measurements
during control exchanges and episodes of peritoni-
tis, and one mean value was obtained for the param-
eters studied from each patient for control and peri-
tonitis exchanges. The mean values obtained were
compared by the paired Student's t test. The null
hypothesis was rejected at P <0.05. All mean val-
ues were reported as the means SEM.
Results
The average time between studies was 37 days
(median, 26 days). There were 15 episodes of peri-
tonitis in nine patients. Patients underwent..an aver-
age of 10 7 measurements of clearance, glucose
absorption, drainage volume, and protein loss dur-
ing control exchanges, and 7 4 during the perito-
nitis exchanges. The dialysis protocol did not eval-
uate if there was residual peritoneal fluid. It was as-
sumed that a 20-mm time for dialysate removal from
the peritoneal cavity was of sufficient duration. The
SEM for dialysate effluent volume during episodes of
peritonitis ranged between 23 to 247 ml, with most
values being between 24 to 60 ml.
One episode of peritonitis failed to yield orga-
nisms on culture, but was associated with symp-
toms of peritonitis and an elevated dialysate count.
The median dialysate cell count when the patient
was first seen for symptoms of peritonitis was 1965/
mm3.
Table 1 details the results from control and peri-
tonitis studies, the initial dialysate cell count, the
organism associated with the peritonitis episode,
and the antibiotics used. Table 2 lists the mean pa-
tient values. The episode of peritonitis on July 18,
patient 8, was associated with a very low peritoneal
clearance of urea. This patient was very ill with
peritonitis and had low serum and dialysate urea ni-
trogen concentrations, suggesting that the measure-
ments obtained were spurious.
Peritonitis was associated with significantly in-
creased urea and creatinine clearances, increased
glucose absorption from the dialysate, increased
protein loss in the dialysate drainage, and decreased
drainage volume.
Discussion
The results obtained during this study further de-
fine the consequences of peritonitis. They are con-
sistent with peritoneal inflammation secondary to
peritonitis. Because glucose is the major osmotic
force during peritoneal dialysis, a more rapid ab-
sorption would be expected to decrease effluent vol-
Table!. Results from control exchanges and from exchanges during episodes of peritonitis
1 CAPD 33 2145.0 4.7 10.4 10.0 5681.0 740.9 24
2 IPD 20 2182.5 19.2 15.4 13.2 7498.8 1400.0 6
3 3 2200.0 1.6 17.8 10.6 6015.7 944.0 12
4 CAPD 12 2323.0 43.2 15.4 11.3 5989.0 1559.8 12
5 CAPD 5 2270.0 24.0 20.0 15.4 5184.0 703.7 18
6 IPD 10 2213.0 12.7 14.0 8.8 3832.1 864.0 12
7 CAPD 6 2229.0 24.2 12.7 5.1 3479,2 890.0 12
8 CAPD 13 2224.0 33.8 12.8 13.8 8155.0 635.0 11
9 IPD 20 2191.0 14.6 16.4 14.3 2779.6 1255.7 6
2220.0* 20.0 15.0" 11.4" 5402.0" 999,Qc
2158.8 30.9 16.1 15.8 3465.4 650.4
2192.0 22.7 17.5 16.2 6338.3 1638.2
2149.0 0.6 18.3 15.0 6938.0 423.0
2090.4 3.6 19.7 18.0 12311.4 1800.5
2111.6 4.6 20.7 14.3 9359.0 1201.2
2204.0 19.5 21.9 18.8 9900.0 991.0
2077.0 2.7 16.3 15.9 12423.0 2722.0
2051.8 9.6 12.2 13.3 11902.0 1155.0
2091.0 0.8 22.5 23.3 12064.0 2221.0
2125.0 10.0 18.2 16.7 9411.0 1423.0
Values are the means SaM. Abbreviations are CAPD, continuous ambulatory peritoneal dialysis; IPD, intermittent peritoneal
dialysis.p < 0.01 (N = 9).
ep < 0.05 (N = 9).
Control exchangesa
Dialysate
Patient no. Date of study No. of exch.
effluent
volume
ml
Na'
loss/gain
mEq/exch.
c,,,.
mi/mm
C, Glucose
absorption
mg/exch.
Protein
loss
mgi exch.
I 7/14 27 2126.5 6.6 8.6 8.5 5688.1 3970.0
18.8
8/6 6 2229.2 3.8 16.7 18.6 5650.9 2288.1
2 1/21 20 2182.5 19.2 15.4 13.2 7498.8 1400.0
3 10/23 3 2200.0 1.6 17.8 10.6 6015.7
6 2433.3 62.6 14.9 10.3 3524.0
4 4/26 6 2213.3 23.9 16.0 12.3 8454.2 2144.6
5 7/26 5 2200.0 24.1 20.0 15.4 5184.0
6 Il/I 10 2213.0 12.7 14.0 8.8 3832.1 864.3
7 5/1 6 2229.0 24.2 12.7 5.1 3479.2 890.6
8 5/25 13 2224.0 33.8 12.8 13.8 8155.1 635.4
9 9/2 6 2136.0 7.2 18.2 16.2 2141.0 1001.9
9/lI 14 2214.3 17.8 15.7 13.4 3053.1 1364.4
a Values are the means 5LM.
Table 2. Mean results from control exchanges and from exchanges during episodes of peritonitis
Control exchangesa
Na Na*
Dialysate loss! Protein Dialysate loss! Protein
Mode No. affluent gain Crea Ccr Glucose loss No. effluent gain Curea Ccr Glucose loss
Patient of of volume mEqi absorption mgi of volume mEqi absorption mgi
no. dialysis exch. ml exch. mi/mi,, mg/exch. exch. exch. ml exeh. mi/mi,, mgIexch. exch.
Peritonitis exchanges'
Tablet. (continued)
Peritonitis exchanges Other factors
Dialysate Initial cell
Date
of
No.
of
effluent
volume
Na
loss/gain
Cure. c. Glucose
absorption
Protein
loss
countiepisode
peritonitis Antibiotic Dialysate
culture
study exch. in! inEq/exch. mi/mm mg/exch. mg/exch. mm3 i.p.
6/5 19 2142.6 36.7 16.8 16.5 2779.1 658.0 2416 Tobramycin
Cephalothin
Klebsielleae sp
7/29 5 2220.0 8.8 13.4 13.2 6073.4 621.6 1800 Ampicillin
Tobramycin anitratus
2/4 6 2192.0 22.7 17.5 16.2 6388.3 1638.2 1965 Cephalothin Staphylococcus
epidermis
9/18 6 2141.7 1.3 20.8 17.1 7195.0 479.3 4900 Cephalothin
Tobramycin
Staphylococcus
epidermis
10/14 6 2156.7 2.5 15.8 12.8 6681.3 366.5 4300 Cephalothin
Tobramycin
Streptococcus
viridans
5/24 6 2066.7 2.5 17.2 18.2 13285.0 2253.4 96 Tobramycin
cloacae
4/3 6 2140.0 10.5 17.1 8.6 11019.0 1449.6 44 Tobramycin Proteus
morganii
Enterohacter7/20 6 2050.0 4.0 18.7 15.8
±0.7
9886.1 1230.9 1340 Cephalothin
Tobramycin aerogenes
Enterhacter11/7 6 2170.0 2.1 20.! 16.8 7454.9 1043.! 2400 Cephalothin
Tobramycin cloacae
11/25 12 2204.2 19.3 21.9 18.8 9900.0 991.3 8900 Vancomycin
Tobramycin
Nogrowth
7/5 6 2071.7 0.6 22.0 19.1 13126.0 4093.4 525 Ampicillin
Tobramycin cepacia
Acinetobacter8/18 6 2081.7 6.0 10.5 12.6 11719.5 1351.5
95.7
2572
.
Tobramycin
anitratu.s
7/10 6 2055.0 7.4 19.1 15.3
I.!
10801.2 920.3 1254 Cephalothin Staphylococcus
epidermis
Candida7/18 6 2048.0 12.3 3.9 8.4
1.6
13223.5 1437.5 1314 Cephalothin
Tobramycin albicans
11/3 6 2091.0 0.8 22.5 23.3 12064.2 2220.5 39600 Cephalothin Staphylococcus
aureus
ume [8]. Although volume contraction is known to
diminish ultrafiltration during peritoneal dialysis, in
this study, blood pressures, weights, and hemato-
crits were similar both with and without peritonitis,
suggesting that intravascular volume was main-
tained [9, 10].
The increase in clearance of urea and creatinine
associated with increased protein losses suggests
that peritonitis induces changes similar to those
seen with the addition of an intraperitoneal vaso-
dilator such as nitroprusside [11]. Changes that
might be occurring during peritonitis are alterations
in peritoneal blood flow, effective peritoneal surface
area, and permeability.
Peritonitis occurring during peritoneal dialysis is
associated with peritoneal inflammation, augment-
ing peritoneal clearance and glucose absorption.
The duration of peritoneal inflammation is un-
known. In patients studied by hourly exchanges 1
week after an episode of peritonitis, peritoneal
clearances and protein losses had returned to base-
line [11].
A possible explanation for the adverse effects of
peritonitis is that the ill catabolic patient does not
ingest an adequate diet whereas protein losses in
dialysate, increased above normal, are continuing.
It appears that peritonitis is associated with an in-
crease in protein losses in dialysate effluent, but ef-
fective therapy rapidly returns peritoneal mem-
brane function.
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